LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

16.03 0.19

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.82

Max

16.14

Pagrindiniai rodikliai

By Trading Economics

Pajamos

6M

Pardavimai

162M

P/E

Sektoriaus vid.

5.664

35.733

Pelnas, tenkantis vienai akcijai

0.52

Pelno marža

3.676

Darbuotojai

1,780

EBITDA

-5M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+56.54% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.6B

Ankstesnė atidarymo kaina

15.84

Ankstesnė uždarymo kaina

16.03

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-08 23:59; UTC

Įsigijimai, susijungimai, perėmimai

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025-09-08 22:02; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Tron Shares Rise After New Investment From Bravemorning

2025-09-08 16:14; UTC

Pagrindinės rinkos jėgos

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025-09-08 16:13; UTC

Pagrindinės rinkos jėgos

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025-09-08 22:56; UTC

Rinkos pokalbiai

Worst May Be Over for New Zealand Retailers -- Market Talk

2025-09-08 22:23; UTC

Rinkos pokalbiai

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025-09-08 21:51; UTC

Rinkos pokalbiai

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025-09-08 21:47; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4B AI Deal With Nebius

2025-09-08 21:33; UTC

Įsigijimai, susijungimai, perėmimai

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025-09-08 21:20; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025-09-08 21:19; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025-09-08 21:18; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025-09-08 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 19:33; UTC

Rinkos pokalbiai

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025-09-08 19:22; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025-09-08 19:02; UTC

Rinkos pokalbiai

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025-09-08 17:29; UTC

Rinkos pokalbiai

Mexican Inflation Seen Little Changed in August -- Market Talk

2025-09-08 16:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025-09-08 16:36; UTC

Rinkos pokalbiai

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025-09-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 16:16; UTC

Uždarbis

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025-09-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-08 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

56.54% į viršų

12 mėnesių prognozė

Vidutinis 25 USD  56.54%

Aukščiausias 25 USD

Žemiausias 25 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat